H
HILLEVAX INC
NASDAQ: HLVX (HilleVax, Inc.)
Kemas kini terakhir: 18 jam lalu2.06
-0.07 (-3.29%)
| Penutupan Terdahulu | 2.13 |
| Buka | 2.13 |
| Jumlah Dagangan | 54,513 |
| Purata Dagangan (3B) | 297,725 |
| Modal Pasaran | 103,207,440 |
| Harga / Buku (P/B) | 0.710 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| EPS Cair (TTM) | -2.15 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.93% |
| Nisbah Semasa (MRQ) | 25.32 |
| Aliran Tunai Operasi (OCF TTM) | -88.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -49.51 M |
| Pulangan Atas Aset (ROA TTM) | -20.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -54.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | HilleVax, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.8 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.38 |
|
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 17.09% |
| % Dimiliki oleh Institusi | 70.85% |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |